CL2018002410A1 - Inhibidores de mcl-1 y métodos de uso de los mismos - Google Patents
Inhibidores de mcl-1 y métodos de uso de los mismosInfo
- Publication number
- CL2018002410A1 CL2018002410A1 CL2018002410A CL2018002410A CL2018002410A1 CL 2018002410 A1 CL2018002410 A1 CL 2018002410A1 CL 2018002410 A CL2018002410 A CL 2018002410A CL 2018002410 A CL2018002410 A CL 2018002410A CL 2018002410 A1 CL2018002410 A1 CL 2018002410A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- mcl
- inhibitors
- tridecaeno
- pentaazaheptaciclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE DA A CONOCER UN COMPUESTO QUE ES ÁCIDO 17-CLORO-5,13,14,22-TETRAMETIL-28-OXA-2,9-DITIA-5,6,12,13,22 PENTAAZAHEPTACICLO [27.7.1.14,7.011,15.016,21.020,24.030,35] OCTATRIAC ONTA-1(37),4(38),6,11,14,16,18,20,23,29,31,33,35-TRIDECAENO-23-CARBOXÍLICO (FÓRMULA I), Y ENANTIÓMEROS Y SALES FARMACÉUTICAMENTE ACEPTABLES DEL MISMO. TAMBIÉN SE DAN A CONOCER COMPOSICIONES FARMACÉUTICAS DE ÁCIDO 17-CLORO-5,13,14,22-TETRAMETIL-28-OXA-2,9-DITIA-5,6,12,13,22 PENTAAZAHEPTACICLO [27.7.1.14,7.011,15.016,21.020,24.030,35] OCTATRIACONTA 1(37),4(38) ,6,11 ,14 ,16 ,18 ,20 ,23,29,31,33,35 -TRIDECAENO-23-CARBOXÍLICO, Y ENANTIÓMEROS Y SALES FARMACÉUTICAMENTE ACEPTABLES DEL MISMO, Y MÉTODOS DE TRATAMIENTO DEL CÁNCER CON TALES COMPUESTOS Y COMPOSICIONES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662326156P | 2016-04-22 | 2016-04-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002410A1 true CL2018002410A1 (es) | 2018-12-07 |
Family
ID=58664658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002410A CL2018002410A1 (es) | 2016-04-22 | 2018-08-23 | Inhibidores de mcl-1 y métodos de uso de los mismos |
Country Status (37)
| Country | Link |
|---|---|
| US (4) | US9840518B2 (es) |
| EP (1) | EP3445767B1 (es) |
| JP (1) | JP6894449B2 (es) |
| KR (1) | KR102388208B1 (es) |
| CN (1) | CN109071566B (es) |
| AR (1) | AR108301A1 (es) |
| AU (1) | AU2017252222B2 (es) |
| BR (1) | BR112018070677B1 (es) |
| CA (1) | CA3020378A1 (es) |
| CL (1) | CL2018002410A1 (es) |
| CO (1) | CO2018008759A2 (es) |
| CR (1) | CR20180499A (es) |
| CY (1) | CY1123186T1 (es) |
| DK (1) | DK3445767T3 (es) |
| DO (1) | DOP2018000222A (es) |
| EA (1) | EA036551B1 (es) |
| ES (1) | ES2791319T3 (es) |
| HR (1) | HRP20200673T1 (es) |
| HU (1) | HUE049591T2 (es) |
| IL (1) | IL262237B (es) |
| LT (1) | LT3445767T (es) |
| MA (1) | MA44721B1 (es) |
| ME (1) | ME03729B (es) |
| MX (1) | MX2018012711A (es) |
| NI (1) | NI201800093A (es) |
| PE (1) | PE20181803A1 (es) |
| PH (1) | PH12018502227A1 (es) |
| PL (1) | PL3445767T3 (es) |
| PT (1) | PT3445767T (es) |
| RS (1) | RS60257B1 (es) |
| SG (1) | SG11201805838UA (es) |
| SI (1) | SI3445767T1 (es) |
| SV (1) | SV2018005742A (es) |
| TN (1) | TN2018000319A1 (es) |
| TW (1) | TWI742074B (es) |
| WO (1) | WO2017182625A1 (es) |
| ZA (1) | ZA201807766B (es) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3782636B1 (en) | 2016-02-04 | 2024-05-15 | The Johns Hopkins University | Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof |
| US11708391B2 (en) | 2016-02-04 | 2023-07-25 | The Johns Hopkins University | Rapaglutins, novel inhibitors of GLUT and use thereof |
| US11066416B2 (en) | 2016-02-04 | 2021-07-20 | The Johns Hopkins University | Rapafucin derivative compounds and methods of use thereof |
| CO2018008759A2 (es) | 2016-04-22 | 2018-09-20 | Astrazeneca Ab | Inhibidores de mcl-1 y métodos de uso de los mismos |
| EP3458459B1 (en) | 2016-05-19 | 2022-04-27 | Bayer Aktiengesellschaft | Macrocyclic indole derivatives |
| TW201904976A (zh) * | 2017-03-31 | 2019-02-01 | 瑞典商阿斯特捷利康公司 | Ｍｃｌ-１抑制劑及其使用方法 |
| TWI781996B (zh) | 2017-03-31 | 2022-11-01 | 瑞典商阿斯特捷利康公司 | 合成ｍｃｌ-１抑制劑之方法 |
| BR112020003180A2 (pt) | 2017-08-15 | 2020-09-15 | AbbVie Deutschland GmbH & Co. KG | inibidores macrocíclicos de mcl-1 e métodos de uso |
| WO2019035899A1 (en) * | 2017-08-15 | 2019-02-21 | Abbvie Inc. | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE |
| EP3710450A1 (en) * | 2017-11-17 | 2020-09-23 | Bayer Aktiengesellschaft | Macrocyclic chlorine substituted indole derivatives |
| US11401278B2 (en) | 2017-11-17 | 2022-08-02 | The Broad Institute, Inc. | Macrocyclic indole derivatives |
| EP3710449B1 (en) * | 2017-11-17 | 2022-07-06 | The Broad Institute, Inc. | Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer |
| JP7234250B2 (ja) * | 2017-11-17 | 2023-03-07 | バイエル アクチェンゲゼルシャフト | 置換大環状インドール誘導体 |
| UY37972A (es) * | 2017-11-17 | 2019-06-28 | Bayer Pharma AG | Derivados de indol macrocíclicos sustituidos con cloro |
| US20210253598A1 (en) * | 2017-11-17 | 2021-08-19 | Bayer Aktiengesellschaft | Aryl annulated macrocyclic indole derivatives |
| TW202014184A (zh) * | 2018-04-30 | 2020-04-16 | 瑞典商阿斯特捷利康公司 | 用於治療癌症之組合 |
| US20220041623A1 (en) | 2018-09-30 | 2022-02-10 | Jiangsu Hengrui Medicine Co., Ltd. | Indole macrocyclic derivative, preparation method thereof and application thereof in medicine |
| TW202344250A (zh) | 2018-11-14 | 2023-11-16 | 瑞典商阿斯特捷利康公司 | 治療癌症之方法 |
| CN111205309B (zh) * | 2018-11-21 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 吲哚类大环衍生物、其制备方法及其在医药上的应用 |
| TWI749404B (zh) * | 2018-11-22 | 2021-12-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑制劑的大環吲哚 |
| US20220396587A1 (en) * | 2019-01-23 | 2022-12-15 | Ascentage Pharma (Suzhou) Co., Ltd. | Macrocyclic fused pyrrazoles as mcl-1 inhibitors |
| SG11202109367WA (en) * | 2019-03-08 | 2021-09-29 | Zeno Management Inc | Macrocyclic compounds |
| TW202106693A (zh) * | 2019-04-30 | 2021-02-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吲哚類大環衍生物、其製備方法及其在醫藥上的應用 |
| TW202100184A (zh) | 2019-05-20 | 2021-01-01 | 瑞士商諾華公司 | Mcl-1抑制劑抗體－藥物結合物及使用方法 |
| MX2021015770A (es) * | 2019-06-21 | 2022-04-12 | Janssen Pharmaceutica Nv | Inhibidores macrociclicos de mcl-1. |
| MX2022000390A (es) | 2019-07-09 | 2022-02-10 | Janssen Pharmaceutica Nv | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. |
| US20220372014A1 (en) * | 2019-10-01 | 2022-11-24 | The Johns Hopkins University | Neuroprotective compounds and methods of use thereof |
| WO2021092061A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Combination treatment for senescence-associated diseases |
| WO2021092053A1 (en) * | 2019-11-08 | 2021-05-14 | Unity Biotechnology, Inc. | Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer |
| MX2022006179A (es) | 2019-11-21 | 2022-06-14 | Janssen Pharmaceutica Nv | Derivados macrociclicos de indol como inhibidores de mcl-1. |
| EP4061820A1 (en) | 2019-11-21 | 2022-09-28 | Janssen Pharmaceutica NV | Macrocyclic sulfonyl derivatives as mcl-1 inhibitors |
| CN115052880A (zh) * | 2019-12-18 | 2022-09-13 | 芝诺管理公司 | 大环化合物 |
| CA3168355A1 (en) | 2020-02-21 | 2021-08-26 | Frederik Jan Rita Rombouts | Macrocyclic indole derivatives as inhibitors of mcl-1 |
| WO2021197295A1 (zh) * | 2020-03-30 | 2021-10-07 | 江苏恒瑞医药股份有限公司 | 一种吲哚类大环衍生物的结晶形式及其制备方法 |
| EP4157852A1 (en) * | 2020-05-29 | 2023-04-05 | JANSSEN Pharmaceutica NV | Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1 |
| JP2023530985A (ja) | 2020-06-19 | 2023-07-20 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｍｃｌ－１の阻害剤としてのｎ結合大環状７－（ピラゾール－５－イル）－インドール誘導体 |
| BR112022025631A2 (pt) | 2020-06-19 | 2023-01-17 | Janssen Pharmaceutica Nv | Derivados de 4-(pirazol-5-il)-indol macrocíclico n-ligados como inibidores de mcl-1 |
| US20230250109A1 (en) | 2020-07-08 | 2023-08-10 | Janssen Pharmaceutica Nv | Macrocyclic ether containing indole derivatives as inhibitors of mcl-1 |
| WO2022032284A1 (en) * | 2020-08-07 | 2022-02-10 | Zeno Management, Inc. | Macrocyclic compounds |
| AU2021385349A1 (en) | 2020-11-24 | 2023-06-22 | Les Laboratoires Servier | Mcl-1 inhibitor antibody-drug conjugates and methods of use |
| EP4008324A1 (en) | 2020-12-07 | 2022-06-08 | Cellestia Biotech AG | Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer |
| AU2021403616A1 (en) | 2020-12-17 | 2023-08-03 | Janssen Pharmaceutica Nv | Branched macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1 |
| MX2023009475A (es) | 2021-02-12 | 2023-08-22 | Janssen Pharmaceutica Nv | Derivados macrociclicos 1,3-con puente 6-cloro-7-pirazol-4-il-1h-i ndol-2-carboxilato y 6-cloro-7-pirimidina-5-il-1h-indol-2-carboxil ato como inhibidores de mcl-1 para el tratamiento del cancer. |
| WO2022251247A1 (en) * | 2021-05-28 | 2022-12-01 | Zeno Management, Inc. | Macrocyclic compounds |
| KR20240019283A (ko) | 2021-06-11 | 2024-02-14 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 저해제와 항암제의 병용 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| CN115490708A (zh) * | 2021-06-18 | 2022-12-20 | 苏州亚盛药业有限公司 | 磺酰胺类大环衍生物及其制备方法和用途 |
| WO2023057484A1 (en) | 2021-10-06 | 2023-04-13 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy |
| WO2023225359A1 (en) | 2022-05-20 | 2023-11-23 | Novartis Ag | Antibody-drug conjugates of antineoplastic compounds and methods of use thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2134685B1 (en) | 2007-04-16 | 2015-09-02 | AbbVie Inc. | 7-nonsubstituted indole derivatives as mcl-1 inhibitors |
| US8445679B2 (en) * | 2007-04-16 | 2013-05-21 | Abbvie Inc. | 7-substituted indole MCL-1 inhibitors |
| PT2379580E (pt) * | 2008-12-22 | 2014-01-20 | Cubist Pharm Inc | Novos agentes antibacterianos para o tratamento de infecções por bactérias gram positivas |
| JP5731538B2 (ja) * | 2009-12-23 | 2015-06-10 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | Ｃｒｔｈ２モジュレーター |
| MX349366B (es) * | 2011-05-19 | 2017-07-26 | Centro Nac De Investigaciones Oncologicas (Cnio) | Compuestos novedosos. |
| US10093640B2 (en) | 2012-09-21 | 2018-10-09 | Vanderbilt University | Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors |
| EP3038618B1 (en) | 2013-08-28 | 2020-10-14 | Vanderbilt University | Substituted indole mcl-1 inhibitors |
| EP3105236B1 (en) * | 2014-02-12 | 2017-10-18 | ViiV Healthcare UK (No.5) Limited | Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication |
| CN106456602B (zh) | 2014-03-27 | 2020-11-24 | 范德比尔特大学 | 取代的吲哚mcl-1抑制剂 |
| AU2015243585B2 (en) * | 2014-04-11 | 2019-08-01 | Bayer Pharma Aktiengesellschaft | Novel macrocyclic compounds |
| US9949965B2 (en) | 2014-10-17 | 2018-04-24 | Vanderbilt University | Tricyclic indole Mcl-1 inhibitors and uses thereof |
| CO2018008759A2 (es) | 2016-04-22 | 2018-09-20 | Astrazeneca Ab | Inhibidores de mcl-1 y métodos de uso de los mismos |
-
2017
- 2017-04-21 CO CONC2018/0008759A patent/CO2018008759A2/es unknown
- 2017-04-21 MA MA44721A patent/MA44721B1/fr unknown
- 2017-04-21 SI SI201730246T patent/SI3445767T1/sl unknown
- 2017-04-21 SG SG11201805838UA patent/SG11201805838UA/en unknown
- 2017-04-21 CN CN201780022366.0A patent/CN109071566B/zh active Active
- 2017-04-21 JP JP2018553226A patent/JP6894449B2/ja active Active
- 2017-04-21 PT PT177207206T patent/PT3445767T/pt unknown
- 2017-04-21 TN TNP/2018/000319A patent/TN2018000319A1/en unknown
- 2017-04-21 MX MX2018012711A patent/MX2018012711A/es unknown
- 2017-04-21 RS RS20200549A patent/RS60257B1/sr unknown
- 2017-04-21 KR KR1020187033540A patent/KR102388208B1/ko active IP Right Grant
- 2017-04-21 AR ARP170101026A patent/AR108301A1/es unknown
- 2017-04-21 CR CR20180499A patent/CR20180499A/es unknown
- 2017-04-21 BR BR112018070677-9A patent/BR112018070677B1/pt active IP Right Grant
- 2017-04-21 PL PL17720720T patent/PL3445767T3/pl unknown
- 2017-04-21 TW TW106113380A patent/TWI742074B/zh active
- 2017-04-21 ES ES17720720T patent/ES2791319T3/es active Active
- 2017-04-21 AU AU2017252222A patent/AU2017252222B2/en active Active
- 2017-04-21 PE PE2018001558A patent/PE20181803A1/es unknown
- 2017-04-21 EA EA201892300A patent/EA036551B1/ru not_active IP Right Cessation
- 2017-04-21 DK DK17720720.6T patent/DK3445767T3/da active
- 2017-04-21 CA CA3020378A patent/CA3020378A1/en active Pending
- 2017-04-21 ME MEP-2020-99A patent/ME03729B/me unknown
- 2017-04-21 EP EP17720720.6A patent/EP3445767B1/en active Active
- 2017-04-21 WO PCT/EP2017/059511 patent/WO2017182625A1/en active Application Filing
- 2017-04-21 US US15/493,210 patent/US9840518B2/en active Active
- 2017-04-21 HU HUE17720720A patent/HUE049591T2/hu unknown
- 2017-04-21 LT LTEP17720720.6T patent/LT3445767T/lt unknown
- 2017-10-23 US US15/790,660 patent/US10196404B2/en active Active
-
2018
- 2018-08-23 CL CL2018002410A patent/CL2018002410A1/es unknown
- 2018-09-12 SV SV2018005742A patent/SV2018005742A/es unknown
- 2018-09-25 NI NI201800093A patent/NI201800093A/es unknown
- 2018-10-05 DO DO2018000222A patent/DOP2018000222A/es unknown
- 2018-10-09 IL IL262237A patent/IL262237B/en unknown
- 2018-10-18 PH PH12018502227A patent/PH12018502227A1/en unknown
- 2018-11-19 ZA ZA2018/07766A patent/ZA201807766B/en unknown
- 2018-12-18 US US16/223,538 patent/US10889594B2/en active Active
-
2020
- 2020-04-28 HR HRP20200673TT patent/HRP20200673T1/hr unknown
- 2020-05-14 CY CY20201100443T patent/CY1123186T1/el unknown
- 2020-12-04 US US17/111,896 patent/US11472816B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002410A1 (es) | Inhibidores de mcl-1 y métodos de uso de los mismos | |
| CL2019001077A1 (es) | Derivados de 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f] isoquinolina útiles en el tratamiento del cáncer. | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| NI201900070A (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2019007129A2 (es) | Modulador del regulador de conductancia transmembrana de fibrosis quística, composiciones farmacéuticas, métodos de tratamiento y proceso para producir el modulador | |
| CO2019000386A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CO2018008916A2 (es) | Compuestos de benzopirazol y análogos de estos | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CL2020001218A1 (es) | Compuestos útiles para inhibir a cdk7. | |
| AR093244A1 (es) | Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2 | |
| AR102981A1 (es) | Inhibidores de la necrosis celular y métodos de preparación de los mismos | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
| UY36875A (es) | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades | |
| EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
| DOP2016000254A (es) | Formulaciones farmeceuticas de inhibidor de la quinasa pan-raf, procedimientos para su preparacion, y metodos de uso. | |
| AR101414A1 (es) | Derivados de pirrolidinona como inhibidores de metap-2 | |
| SV2016005313A (es) | Derivados de carboxamida | |
| CL2021002309A1 (es) | Compuestos útiles en la terapia del vih | |
| UY36123A (es) | Derivados de carboxamida | |
| CO2021007172A2 (es) | Sales cristalinas de un inhibidor de calicreína plasmática | |
| TR201819805T4 (tr) | Flavaglin türevleri̇. | |
| AR105400A1 (es) | Inhibidores de jak1 | |
| CO2021008962A2 (es) | Derivados activos de éster de testosterona, composiciones y usos de los mismos | |
| AR113817A1 (es) | Compuestos útiles para inhibir a cdk7 |